FDA Approves Lenalidomide (Revlimid) for Mantle Cell Lymphoma

On June 5, 2013, the U. S. Food and Drug Administration approved lenalidomide capsules (REVLIMID), for the treatment of patients with mantle cell lymphoma (MCL) whose disease has relapsed or progressed after two prior therapies, one of which included bortezomib.

Source:

http://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm355438.htm